<DOC>
	<DOCNO>NCT01475266</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety patient non-muscle invasive bladder cancer histologically diagnose stage Ta G1 G2 randomize either EO9 placebo group TURBT .</brief_summary>
	<brief_title>Single Immediate Instillation EO9 After TURBT Patients With Non-muscle-invasive Bladder Cancer ( NMIBC )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Apaziquone</mesh_term>
	<criteria>1 . Patients provide write informed consent 2 . Patients urothelial cell carcinoma bladder clinically apparent stage Ta , grade G1G2 satisfy follow criterion : The maximum number tumor 5 . Each tumor diameter : ≤ 3.5 cm . 3 . Age : ≥20 year old enrollment . 4 . The function major organ adequate , follow test value criterion satisfy : Neutrophil count ≥1,500/μL Platelet count ≥10×10^4/μL Hemoglobin ≥10 g/dL 1 . Patients single , primary bladder cancer &lt; 0.5 cm . 2 . Patients CIS lesion bladder history thereof . 3 . Patients history stage Ta , histological grade G1 G2 disease . 4 . Patients experience recurrence within 4 month follow TURBT prior NMIBC ( duration last TURBT cystoscopic confirmation present recurrence within 4 month ) . 5 . Patients without least threemonth cystoscopically confirm recurrencefree interval last TURBT time study screen 6 . Patients bladder tumor histological diagnosis urothelial carcinoma bladder history thereof . 7 . Patients administer EO9 past . 8 . Patients administer investigational drug within past 30 day . 9 . Patients medical condition would make unsafe undergo TURBT general spinal anesthesia .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>NMIBC</keyword>
	<keyword>TURBT</keyword>
	<keyword>Apaziquone</keyword>
	<keyword>EOquin</keyword>
	<keyword>Immediate instillation</keyword>
</DOC>